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Executive Summary

Antibiotic-associated diarrhea (AAD) including Clostridium difficile associated diarrhea
(CDAD) has been a challenging topic for the healthcare industry. AAD is caused by the
disruption of normal microbial balance along with the gastrointestinal (GI) tract due to the use of
an antibiotic. AAD not only increases healthcare cost burden but also increases morbidity and
mortality among vulnerable populations such as the elderly. Antibiotic use is very common
among the elderly and it is the responsibility of healthcare providers to take appropriate measures
in preventing complications associated with antibiotic use among these populations. Therefore,
exploring measures that are cost-effective to prevent the complication of antibiotic use in
vulnerable populations is important for any provider. The PICOT question for this study is as
follows: In patients 65 years and older (P), how does the use of probiotic (I) compared to non-use
of probiotic therapy (C) affect the risk of antibiotic-associated diarrhea (O) during or within 12
weeks of antibiotic therapy (T)?
Easily available, tolerable, and cost-effective probiotics can be life-saving measures for
many elderly populations if it is effective in preventing AAD and CDAD. Probiotics are
generally well documented for the benefits they provide on gastrointestinal and immune health.
It is also considered safe to consume for most age groups. Elderly patients are admitted or
readmitted frequently to the hospital with infections such as urinary tract infection (UTI), sepsis,
and pneumonia every day and they encounter many complications due to antibiotic treatment and
hospitalization itself. Hospitalization can be more devastating to elderly patients as they are
more prone to complications related to hospitalization such as delirium, debility, decrease
mobility, skin breakdown, and falls. Based on the literate review of twelve articles that include
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mostly systemic reviews and randomized control trials (RCTs), there are some promising results
in preventing AAD and CDAD with probiotic use.
This project seeks to introduce and implement the protocol of prescribing probiotic
Culturelle along with the antibiotic in the medical-surgical geriatric unit of the hospital. The
main purpose of this study is to evaluate the effect of probiotics in preventing AAD and CDAD
when concurrently used with antibiotics among the elderly.
Rationale for the Project
The elderly who are more susceptible to disease because of diminished physiological
reserve and immune response are more likely to receive long-term antibiotics (Mallina et al.,
2018). The practice of prescribing antibiotics has also been drastically changed over the last
decade due to the emergence of many drug resistance infections including Clostridium difficile
infection (CDI). When it comes to elderly patients, it is important to take preventive measures
for AAD and CDAD. The cost burden and mortality related to ADD including CDAD among
the elderly is high in today’s healthcare industry. According to Mallina et al., “90% of all
CDAD attributed deaths occur in person over the age of 65” (2018, p. 85). According to Allen et
al. (2012), approximately 5%-39% of people suffer from AAD during or even up to 12 weeks
following antibiotic therapy and about 15%-35% are associated with Clostridium difficile.
Probiotics have been well documented as an effective measure to prevent or improve AAD
among the pediatric and adult population. Probiotic has a minimal adverse effect and can be
cost-effective measures if proven to have a role in preventing or even improving ADD symptoms
among the elderly population. Probiotics have been taken in the form of fermented foods for
many centuries and are generally considered safe to use among the elderly unless the presence of
serious health conditions such as a compromised immune system (Smith, 2016). So, it would be
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beneficial to know the role of probiotics when receiving antibiotics among elderly patients. This
evidence can be applied into practice to provide the best possible care for the elderly population
to increase their quality of life and experience.
Literature Review
A systematic review of 26 RCTs by Lau and Chamberlain (2016) suggested that CDAD
was significantly reduced by the use of probiotic RR = 0.395 [95% CI 0.294-0.531], p <
0.001). Lau and Chamberlain (2016) found very few trials on elderly patients suggesting a need
for more randomized placebo-controlled trials for elderly patients who are at the highest risk of
developing AAD and CDAD. Similarly, a systematic review conducted by Xie, Li, Wang, Li,
and Chen (2015) showed only one trial where Bacillus licheniformis was effective against AAD
in older patients; all other probiotics selected in trials did not show a significant reduction in the
risk of AAD and CDAD among older adults. Xie et al. (2015) expressed difficulty concluding as
there was not adequate data published on the elderly population suggesting a need for a more
robust, large sample, and multi-center double-blind RCTs. Wright, Wright, and Murray (2015),
who conducted a multi-center randomized controlled pilot study of 87 elderly patients age
greater than 65 years, compared an active Yakult (contains commercially available probiotic
strain, Lactobacillus casei) with placebo. The result showed no significant difference in the
incidence of diarrhea between Yakult and placebo groups with Fisher’s exact test, p = 0.729
(Wright, Wright, & Murray, 2015).
Pattani, Palda, Hwang, and Shah (2013) conducted a systematic review and meta-analysis
of 16 RCTs. Their analysis showed that there was a significant reduction in the risks of AAD
and Clostridium difficile infection (CDI) among the patients who received probiotics compared
to placebo or no treatment. Meta-analysis showed benefits of probiotics on outcomes regardless
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of the type of probiotics, quality of a study, and duration of follow-up, but only good quality
studies showed significant results for both AAD and CDI (Pattani, Palda, Hwang, & Shah,
2013). Pattani and colleagues (2013) concluded that probiotics can be recommended to prevent
both AAD and CDAD for inpatients adults who require antibiotic therapy. Avadhani and Miley
(2011) conducted a meta-analysis of eight RCTs that included hospitalized adult patients of age
18 to 80 years who received antibiotics with the exclusion of pre-existing gastrointestinal disease
(GI) and immunocompromised patients. Avadhani and Miley (2011) found RR of 0.56 at 95%
CI (0.44-0.71) p < 0.001 for AAD and RR of 0.29 at 95% CI (0.18-0.46), p < 0.001 for
CDAD. The study showed a protective effect of probiotics with significant relative risk
reduction (RRR) for both AAD (44%) and CDAD (71%) in probiotic groups compared to
placebo or no treatment group when probiotics were used concurrently with antibiotics
(Avadhani & Miley, 2011). Safdar, Barigala, Said, and McKinley (2008) indicated that
Lactobacillus acidophilus based probiotic Florajen® was well tolerated without any major
adverse effect among elderly with multiple comorbidities. Safdar and associates (2008) found
37% AAD in placebo group and 17% in Florajen® group (RR =1.63 ([95% CI 0.73-3.65], p =
0.15).
A randomized, double-blind, placebo-controlled trial conducted by Ehrhardt et al. (2016)
showed a hazard ratio of 1.02 (95% CI, .55–1.90; p = .94) in Saccharomyces boulardii group
when compared to the placebo group. Ehrhardt et al. (2016) claimed that this was one of the
largest RCTs that studied a total of 477 patients; however, 185 patients who did not complete the
documentation for daily stools throughout the observation were also included. The trial was
stopped due to recruitment issues and low estimated power (Ehrhardt et al., 2016). Mallina et al.
(2018) conducted a retrospective cohort study using probiotic ACTIMEL containing
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Lactobacillus casei, Lactobacillus bulgaricus, and Streptococcus thermophiles found no
significant decrease in the incidence of CDAD in patients receiving probiotics (OR = 0.9 ([95%
CI 0.27-2.91], p = 0.8). However, Mallina and colleagues (2018) mentioned that reported
CDAD rates may be influenced by the lack of antibiotic resistance test of the strains presented in
ACTIMEL.
A pilot RCT conducted by Barker et al. (2017) found a significant improvement in
diarrhea symptoms with probiotic adjunct therapy along with antibiotic therapy in patients with
initial mild to moderate CDAD. The purpose of the study was to determine the feasibility and
health outcome of probiotic use. A total of 31 patients were randomized into a daily placebo or a
single multi-strain oral probiotic capsule for four weeks. The study showed that the median
duration of diarrhea for the placebo group was one day longer in comparison to the probiotic
group (p=0.039). Similarly, the outcome of total diarrhea days for the placebo group was 12
days and for the probiotic group was 3.5 days respectively. All outcome studies including
diarrhea rate (0.1 for probiotic and 0.3 for placebo) were improved in the probiotic group (Barker
et al., 2017).
A systematic review and meta-analysis of a total of 82 RCTs by Hempel et al. (2012)
concluded that probiotic use was associated with a decrease in AAD incidents (RR = 0.58 [95%
CI 0.50-0.68], p < 0.001). This systematic review study broadly evaluated the available evidence
on the role of probiotics in preventing or treating AAD. Study analysis included all age groups
including children, adult, and elderly patients. However, there were only 3 RCTs exclusively in
elder patients. Article by Cai et al. (2018) explored the efficacy and tolerability of various
probiotics used in preventing or treating AAD with the purpose of ranking and determining the
optimal regimen. The authors conducted a meta-analysis of 51 RCTs that used different kinds of
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probiotics therapy to prevent AAD and it was concluded that Lactobacillus rhamnosus GG
(LGG) was ranked the highest in term of both tolerances (OR=0.44, 95% CI 0.23-0.84) and
effectiveness (OR=0.28 95% CI 0.17-0.47) in preventing AAD (Cai et al., 2018). A pragmatic
participatory evaluation (PPE) design-retrospective cohort study by van Wietmarschen, Busch,
van Oostveen, Pot, and Jong (2020) found antibiotic with probiotic use group had significantly lower
AAD in comparison to no probiotics use (20% vs 36%, p = 0.022). The authors had also mentioned in

their review of literature that the previous studies that showed no difference between
multispecies probiotics in comparison to placebo in preventing AAD in older (greater or equal to
65 years) had probiotics administered up to 7 days after start of antibiotics rather than at the start
of antibiotic therapy (van Wietmarschen et al., 2020). Therefore, the outcome might be different
if probiotics are given along with antibiotics from day one and continue after completion of
antibiotics up to 12 weeks to see true results of the effectiveness of probiotics.
Project Stakeholders
Primary stakeholders for this project include patients or families and providers. Other
stakeholders for this change project may include the senior leadership team, the infection control
team, nurses who provide direct patient care to these patients, nursing assistants, the manager in
this particular unit, supervisor, charge nurses, geriatric physician or nurse practitioner, and
clinical educator. The evidence-based practice (EBP) committee of the hospital will be also an
important stakeholder of this project.
Implementation and Evaluation
This project will be carried out in the medical-surgical geriatric unit of the hospital. The
patients admitted in this unit are in fairly stable condition who does not need a close monitor or
cardiac monitor. Severely immunocompromised patients will not be included in this protocol
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unless specifically ordered by a physician. Also, these patients should be able to take pills via
the oral or PEG route.
Another important aspect of this project is to educate patients/families and nurses
regarding assessing stool consistency using the Bristol Stool Scale. Nurses need education on
AAD/CDAD and the importance of accurate assessment of stools as well as accurate and proper
documentation of stools in an electronic charting system that helps the nurse manager to generate
accurate data on the AAD and CDAD rate. The computer charting system already has a detailed
description along with the picture of the Bristol Stool Scale for nurses to pick options from type
1 to type 7 stool. That ensures accurate charting on the types of stool. There will be a copy of
the Bristol Stool Scale chart available for patients or can be placed on the wall of the patient’s
bathroom. Nurse Manager to ensure that all nurses are updated on online mandatory courses
regarding AAD/CDAD and use of the Bristol stool scale. Probiotic Culturelle will be prescribed
daily for all the patients who need antibiotics. There will be a copy of the excel spreadsheet that
is provided to the patient or caregiver along with a Bristol Stool Scale to record the number of
stools and consistency every day until 12 weeks. The primary nurse will be responsible for
educating the patient/family regarding the excel sheet and the Bristol stool scale recording.
Discharge follow-up will be made every week by the nurse clinician until 12 weeks to ensure
medication and stool record compliance and will be recorded/updated in an electronic health
record by the clinician.
The final step of this project will be analyzing the overall data and preparing the final
results in a numeric form such as a frequency and percentage or rate as well as a visual form
such as a chart. Evaluation of this project includes comparing the AAD rate, CDAD rate,
number of diarrhea days, and length of hospitalization days to the previous monthly and
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quarterly rates. The nurse manager of the floor who conducts key performance indicators (KPIs)
every end of the month will be responsible for preparing a report utilizing the computer database.
Monthly and quarterly AAD rate, CDI rate, diarrhea days, and length of hospitalization days will
be compared to the prior rate to see progress/success of this project. Reduction in the monthly
AAD rate, CDI rate, diarrhea days, and length of the hospitalization days for typical infections
will indicate the succession of this project. However, at this time, this project will not be
implemented on the floor as it was planned due to a current pandemic situation and a change in
the employment status. So the benchmark project will be utilized for this class’s requirement.
If the situation allows, this project will be implemented in a similar population and
similar hospital floor in the future. At this time, the PowerPoint presentation of this project will
be presented to peers in this class.
Timetable/Flowchart
From day one of antibiotic initiated, the probiotic will be given along the course of the
antibiotic. Any time a physician order an antibiotic in the electronic charting system, the order
for probiotic Culturelle that consists of LGG will tag along with the order automatically.
However, the physician will have a choice to exclude the Culturelle order if there is any
contraindication or any other condition that the physician does not want to order probiotic. Once
the antibiotic and probiotic are ordered by the physician and verified by the pharmacy, they will
be administered by the primary nurse every day along with antibiotics. The nurse will provide
education on antibiotics, AAD/CDAD, and probiotics and how to keep a record every day. The
nurse will provide a copy of the Bristol stool chart sheet and excel sheet that includes the date,
number of stools, and consistency for the patient to keep the record for the next 12 weeks. The
nurse will assure the patient understands the importance of accurate reporting of stool
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consistency and the number of stools. The nurse will be responsible for charting consistency and
times of stools that occurred in every shift in the electronic charting system during
hospitalization. The discharge nurse to follow with the patient every week until 12 weeks to
keep updated records on the patient’s chart. The Nurse Clinician or manager will be responsible
for pulling data from Electronic Health Record (EHR) and prepare the AAD rate, CDI rate, days
of diarrhea days every end of the month.
Data Collection Methods
Electronic Health records will be utilized to calculate the AAD rate, CDAD rate, number
of diarrhea days, and length of hospitalization days. Discharge follow-up will be made via
telephone every week by the nurse clinician until 12 weeks which will be recorded/updated in an
electronic health record. These all data will be utilized by the nurse manager to generate
aggregate data.
Cost/Benefit analysis
It is assumed that the cost to the patients due to adding probiotics would be minimum per
course per patient when compared to the risk and cost associated with AAD and CDAD. Some
of the research studies conducted on the cost-effective analysis of the use of probiotics in
preventing AAD and CDAD showed very positive and promising results. A research study
conducted by the Provincial Healthcare system in Canada found that the average overall cost per
patient who was treated with oral probiotics was Canadian dollar (CAN$) 327 in comparison to
CAN$ 845 for the patient who did not receive probiotic therapy during antibiotic therapy (Leal,
Heitman, Conly, Henderson, & Manns, 2016). The direct cost of treatment with probiotics was
CAN$ 24 per patient per course of treatment (Leal et al., 2016). This study also found that the
risk of CDAD was reduced from 5.5% to 2% among the probiotics group (Leal et al., 2016).
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Therefore, easily available probiotics will be cost-effective in comparison to the cost burden
associated with AAD and CDAD if proven to have protective effects on the elderly population.
Discussion of the Results
Official evaluation of this benchmark study is not available at this time. The clinical
instructor of this class has provided positive feedback on this project. Also, this project has
received positive feedback from the peers of this class. This author is very hopeful to utilize this
benchmark project in the real work environment to receive actual results in clinical settings.
Recommendations
AAD and CDAD are the complications associated with antibiotic use that impact the
mortality and morbidity among vulnerable populations such as the elderly. Research studies
have shown positive effects of using probiotics during antibiotic therapy in preventing or
decreasing the symptoms of AAD and CDAD. Easily available and tolerated probiotics can be
life-saving as well as cost-effective measures if they help to prevent and improving AAD and
CDAD symptoms among the elderly. Consumption of probiotics is very common in our society
due to the health benefit they offer. Therefore, it is recommended to prescribe or advise to take
probiotics preferably LGG along with antibiotics to reduce the risk of AAD and CDAD among
the elderly high-risk population.
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Appendix A

Flowchart

Day 1
•

•
•

Patient on Probiotic along
with antibiotics
Patient education on Bristol
Stool Scale
Provide excel sheet to
patient/family for record
keeping

Daily record of stools for 12 weeks
•
•

Record on EHR every shift by primary nurse
If discharged, discharge follow up by clinician
or charge nurse every week and update record
keeping

End of every month
•
•
•

•

Aggregate data from EHR and
patient record
Run monthly report on unit’s
AAD, and CDAD rate
Run separate report on AAD,
CDAD, and diarrhea days for
patients who have been discharged.
Compare monthly rates
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Appendix B

Sample: Patient recording sheet

Date

Patient Name:
Number of stool
per day

Consistency
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